These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 4039653)

  • 1. Does treatment influence the natural history of patients with hypertrophic cardiomyopathy?
    McKenna WJ
    Drugs; 1985 Mar; 29 Suppl 3():53-6. PubMed ID: 4039653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia.
    McKenna WJ; Oakley CM; Krikler DM; Goodwin JF
    Br Heart J; 1985 Apr; 53(4):412-6. PubMed ID: 4039188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Arrhythmias in hypertrophic cardiomyopathy. Significance and therapeutic consequences].
    McKenna WJ; Kleinebenne A
    Herz; 1985 Apr; 10(2):91-101. PubMed ID: 2580767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arrhythmia and prognosis in hypertrophic cardiomyopathy.
    McKenna WJ
    Eur Heart J; 1983 Nov; 4 Suppl F():225-34. PubMed ID: 6686539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of hypertrophic cardiomyopathy in children.
    Seggewiss H; Rigopoulos A
    Paediatr Drugs; 2003; 5(10):663-72. PubMed ID: 14510624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonsustained ventricular tachycardia as a predictor for sudden death in patients with idiopathic dilated cardiomyopathy. The role of amiodarone treatment.
    Castelli G; Ciaccheri M; Cecchi F; Troiani V; Nannini M; Marconi P; Olivotto J; Montereggi A; Dolara A
    G Ital Cardiol; 1999 May; 29(5):514-23. PubMed ID: 10367218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sudden death and hypertrophic cardiomyopathy: a review.
    Ly HQ; Greiss I; Talakic M; Guerra PG; Macle L; Thibault B; Dubuc M; Roy D
    Can J Cardiol; 2005 Apr; 21(5):441-8. PubMed ID: 15861263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Ambulatory ECG in cardiomyopathies].
    Mestroni L; Miani D; Neri R; Di Lenarda A; Camerini F
    G Ital Cardiol; 1987 Dec; 17(12):1139-44. PubMed ID: 3503812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure of amiodarone to prevent ventricular fibrillation (sudden death) in hypertrophic cardiomyopathy.
    Mercereau D; Kubac G; Klinke WP
    Can J Cardiol; 1989 Mar; 5(2):77-80. PubMed ID: 2706577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertrophic cardiomyopathy in childhood and adolescence - strategies to prevent sudden death.
    Ostman-Smith I
    Fundam Clin Pharmacol; 2010 Oct; 24(5):637-52. PubMed ID: 20727015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of incessant ventricular tachycardia in hypertrophic cardiomyopathy associated with improvement of severe left ventricular dysfunction.
    McAreavey D; Fananapazir L
    Pacing Clin Electrophysiol; 1992 Nov; 15(11 Pt 1):1642-5. PubMed ID: 1279528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mid-ventricular obstructive hypertrophic cardiomyopathy associated with an apical aneurysm and sustained ventricular tachycardia: a case report].
    Kono K; Higashi T; Hara K; Mori S; Ito I; Shinbo G; Anzai R; Yagi H; Tamano K; Horinaka S; Matsuoka H
    J Cardiol; 2001 Dec; 38(6):343-9. PubMed ID: 11806092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hypertrophic cardiomyopathy with midventricular obstruction of the left ventricle (MVO)--case report].
    Pizoń T; Rajzer M; Wojciechowska W; Jastrzebski M; Olszanecka A; Rojek M; Jurczyszyn A; Czarnecka D
    Przegl Lek; 2015; 72(5):271-5. PubMed ID: 26817332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy.
    Fananapazir L; Leon MB; Bonow RO; Tracy CM; Cannon RO; Epstein SE
    Am J Cardiol; 1991 Jan; 67(2):169-74. PubMed ID: 1987718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of ventricular arrhythmias in patients with hypertrophic cardiomyopathy.
    Almendral JM; Ormaetxe J; Martínez-Alday JD; Villacastin JP; Arenal A; Pastor A; Medina O; Peinado R; Delcan JL
    Eur Heart J; 1993 Nov; 14 Suppl J():71-2. PubMed ID: 8281967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arrhythmia and hypertrophic cardiomyopathy.
    Shakespeare CF; Keeling PJ; Slade AK; McKenna WJ
    Arch Mal Coeur Vaiss; 1992 Dec; 85 Spec No 4():31-6. PubMed ID: 1307192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sudden death and obstructive hypertrophic cardiomyopathy].
    Baille N
    Ann Cardiol Angeiol (Paris); 1985 Mar; 34(3):155-60. PubMed ID: 3890678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ventricular tachycardia in "end stage" hypertrophic cardiomyopathy: a role of dronedarone.
    Nanda S; Levin V; Martinez MW
    Minerva Cardioangiol; 2012 Dec; 60(6):637-42. PubMed ID: 23147440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of the risk of sudden death in hypertrophic cardiomyopathy].
    Sadoul N; de Chillou C; Aliot E; McKenna WJ
    Arch Mal Coeur Vaiss; 1999 Apr; 92 Spec No 1():65-73. PubMed ID: 10326160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.
    Vieira AP; Adragão PP; Santos KR; Morgado FB; Cavaco DM; Rossi R; Abecasis M; Neves JP; Bonhosrst D; Gomes JL; Gomes RS
    Rev Port Cardiol; 2005 Mar; 24(3):407-15. PubMed ID: 15929624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.